June 2021- Global Life Science Business Partnering - News & Updates

Highlights of June 2021

  1. Quadria Capital to buy 15% stake in Encube Ethicals valuing firm at US$800 Million.
  2. Ocugen pays US$15 million upfront to Bharat Biotech for Covaxin rights in Canada.
  3. Ipca Labs acquires 13.09% stake in Trophic Wellness for Rs 21.20 Crores (~US$3Million).
  4. Strides Pharma joins hands with Ennaid to produce oral medication for mild COVID-19.
  5. Reddy's Lab, Fortress Biotech Ink DFD-29 Collaboration Pact for Chronic Skin Disorder.
  6. Sun Pharma, Ferring Pharmaceuticals ink pact to introduce obstetric drug in India.
  7. Hyderabad's Rockwell ties up with Dr Reddy's lab for freezers to store Sputnik V vaccine.
  8. Cadila, Bayer to extend JV partnership for three years.
  9. Chemiphar and Sumitomo Dainippon partner on novel CNS candidate NC-2800.
  10. Sigrid Therapeutics enters manufacturing deal.
  11. Novo Nordisk enters agreement with Heartseed.
  12. Arrowhead links with Horizon on RNAi therapeutic for uncontrolled gout

    Highlights at Aagami:

    1. New Client Wins:
      1. A Swedish biotech company has chosen Aagami to support them for Partnering including Investment, Licensing, Co-development, and other forms for their innovative therapies in Rheumatoid Arthritis and Covid-19.
      2. Illinois US based client with technology platforms focused on delivering, biodegradable revolutionary materials leveraging natural polymers which can be infinitely recycled or returned to Nature’s nutrient cycles. Replacement to Plastic and Leather, incredible performance and variety of Applications.
    2. Assignment Extensions: Impressed by our expertise and support, 2 clients extended their contract with Aagami.
    3. BIO Digital Convention 2021: With 45+ strategic one-on-one meetings with CXOs worldwide, Aagami had a very busy and productive conference.

     

    INFOCUS: Select opportunities available at Aagami:

     

    For Acquisition/Licensing:

    1. Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package, & IP - Information Memorandum is available for review.    
    2. Patented Docetaxel and Complex Generic Doxorubicin – Few Data room diligence and Term Sheet level conversations going on.

     

    For Investment/Partnering/Licensing:

    1. Licensing, Co-development, for innovative therapies in Rheumatoid Arthritis and Covid-19 (Phase 2).
    2. Lidocaine 10% Topical Patch; NDA accepted by US FDA in Oct 2020 (Licensing for US available) – Ideal for Pharma companies and also wholesalers/distributors.
    3. Opportunity to invest in Portable Point-Of-Care MRI for Neuro Imaging and Interventions.
    4. Series A - $25M Financing: Midwest US based Pharma’s First-in-Class Non-Opioid Analgesic for Pain Relief – Seeking funding and partnerships.
    5. Seeking Licensing/Strategic partnerships our client’s botanical drug candidate (NFL-101) without nicotine for smoking cessation. It is delivered subcutaneously, twice, one week apart.

     

          On the market product for Licensing:

    1. On the Market Pro-immunity supplement capsules of Rapid and synchronized dormancy-broken (awakened) Kyoho grape seed endosperm from our Japanese client.
    2. Japanese High Precision-Surface Plasmon Resonance (HP-SPR) Cells Screening by laser within 1 hour. 10,000 to 1 Million times higher sensitivity compared to existing commercial instruments.

×
Twitter